Moexipril

CAT: 0804-HY-117281Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-117281Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Moexipril is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride) . Moexipril exhibits antihypertensive and neuroprotective effects[1]-[4].
CAS Number
[103775-10-6]
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
Angiotensin-converting Enzyme (ACE) ; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/moexipril.html
Solubility
10 mM in DMSO
Smiles
O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=C(C=C(OC)C(OC)=C3)C1)O
Molecular Formula
C27H34N2O7
Molecular Weight
498.57
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concise review. J Clin Pharmacol, 2004. 44 (8) : p. 827-36.|[2]Friehe H, et al. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung. 1997 Feb. 47 (2) :132-44.|[3]Edling O, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275 (2) :854-63.|[4]Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol. 1999 May 28;373 (1) :21-33.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched

Popular Products